News for Celularity Inc. (CELU)

Celularity (CELU), a biopharmaceutical company, has expressed its approval of a recent decision by the Centers for Medicare & Medicaid Services (CMS) to postpon

Action delays to January 1, 2026, the effective date of a Biden-era Medicare LCD for skin substitute products used to treat diabetic foot ulcers and venous leg

Highlights the unique therapeutic potential of Celularity clinical-stage candidate CYNK-001 in age-related diseases FLORHAM PARK, N.J., April 07, 2025 (GLOB

Natalin and Acelagraftâ„¢ are the latest additions to Celularity's portfolio of HCT/P 361 products for use in the treatment of partial and full thickness acute

Leverages Celularity World-class Manufacturing Capabilities FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. ( CELU) (”œCelularity”

FLORHAM PARK, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Celularity issues the following announcement on behalf of the members of the MASS Coalition: MASS Coali

Celularity (CELU) has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing its Quarterly Report, boosting stock price by 3.04%.

Celularity filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024, and is now current with its quarterly report filings Reported Total Net Revenue for the Three Months and the Nine Months ending September 30, 2024, are consistent with last guidance, with significant growth over the same periods in 2023

FLORHAM PARK, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (”œCelularity” or the ”œCompany”), a regenerative medicine company

Celularity (CELU) notified by Nasdaq for late filing of quarterly report.

PETALING JAYA: Genting Bhd held a groundbreaking ceremony on Wednesday for its first stem cell facility, Fontaine Vitale, to be developed and operated...

Celularity (CELU) resolves Nasdaq compliance issue, stock to continue trading.

FLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. ( CELU) (”œCelularity”), a regenerative and cellular medicine company, today announce

FLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (

Artelo Biosciences, Inc. (ARTL) experienced a significant drop in its stock price, falling 5.39% to $1.15 with a trading volume of 18,680 shares and a turnover

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.13%

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company...

NEW YORK, 07 août 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS ; Nasdaq : CLLS), société de biotechnologie de stade clinique, qui...

Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.